Goldline Pharmaceutical Ltd. (GOLDLINE) — Tipsheet https://tipsheet.markets/company/goldline/ Every Tipsheet Editorial note covering Goldline Pharmaceutical Ltd. (GOLDLINE), newest first. Grounded in BSE/NSE primary-source filings. en-in Tue, 28 Jul 2026 14:38:34 GMT Goldline promoter lifts stake to 29.27% with open-market buy https://tipsheet.markets/goldline-goldline-promoter-lifts-stake-to-29-27-with-open-market-buy-111735/ https://tipsheet.markets/goldline-goldline-promoter-lifts-stake-to-29-27-with-open-market-buy-111735/ Tue, 23 Jun 2026 20:40:44 GMT Swapan Khandelwal bought 60,000 shares (0.62% of equity) on 22 June. No pledging. For a nano-cap with a market cap of just ₹42 cr, it's a rare vote of confidence. Swapan Khandelwal bought 60,000 shares (0.62% of equity) on 22 June. No pledging. For a nano-cap with a market cap of just ₹42 cr, it's a rare vote of confidence.

What’s new

  • Promoter Swapan Khandelwal bought 60,000 shares, raising his holding from 28.65% to 29.27%.
  • The purchase was made in the open market on 22 June 2026 with no pledging.
  • For a nano-cap with a ₹42 cr market cap and thin trading, insider buying is a strong conviction signal.

Why it matters

In a thinly traded nano-cap, a promoter putting fresh cash into the stock reduces the perceived risk of overhang and signals that the person closest to the business sees value. Khandelwal's stake is now 29.27%, unencumbered, adding weight to the narrative. The disclosure is fresh and triggers 'promoter buying'—unconditionally important under the scoring framework.

What we’re watching

  • Whether Khandelwal continues to buy in the coming weeks.
  • Impact on floating stock: 0.62% is small but meaningful for liquidity.
  • Next quarterly results to see if the profit trajectory holds.

The full read

Goldline Pharmaceutical promoter Swapan Khandelwal just put his own money on the line. In an open-market purchase on June 22, he bought 60,000 shares, 0.62% of the company's equity, lifting his stake from 28.65% to 29.27%. The shares are unencumbered. For a nano-cap with a market cap of just ₹42 crore and thin daily volumes, insider buying is a powerful signal. It cuts the risk of overhang and says the person running the company sees value. Khandelwal already held 28.65%; adding 0.62% more is a small percentage but a large statement. In a stock where every trade moves the price, a promoter buying in the open market is about the clearest vote of confidence you get.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial Goldline Pharmaceutical's profit jumps 45% to ₹411.71 lacs in FY26 https://tipsheet.markets/goldline-goldline-pharmaceutical-s-profit-jumps-45-to-411-71-lacs-in-fy26-107057/ https://tipsheet.markets/goldline-goldline-pharmaceutical-s-profit-jumps-45-to-411-71-lacs-in-fy26-107057/ Tue, 09 Jun 2026 18:56:22 GMT The nano-cap drugmaker's first full-year audited results show profit outpacing revenue growth. Revenue rose 11% to ₹3,119.76 lacs. The nano-cap drugmaker's first full-year audited results show profit outpacing revenue growth. Revenue rose 11% to ₹3,119.76 lacs.

What’s new

  • Net profit rose 45% to ₹411.71 lacs for the year ended March 31, 2026.
  • Revenue grew 11% to ₹3,119.76 lacs.
  • The board appointed an internal auditor alongside approving the results.

Why it matters

This is the first full-year audited result for Goldline, a recently listed nano-cap. The 45% profit jump on 11% revenue growth points to lower costs or better pricing. The unmodified auditor's report provides a clean baseline for a company still proving itself.

What we’re watching

  • Whether the profit surge holds in coming quarters or reflects one-off items.
  • How the new internal auditor influences governance at this early stage.
  • Growth trends from a small revenue base.

The full read

Goldline Pharmaceutical, a recently listed nano-cap, posted 45% profit growth in its first full-year audited results. Net profit hit ₹411.71 lacs for FY26, up from ₹283.43 lacs the prior year. Revenue grew 11% to ₹3,119.76 lacs, meaning the bottom line outpaced the top line by a wide margin. That points to improved profitability for the small drugmaker. The auditor's report is unmodified. The board also brought on an internal auditor, a standard governance move for a newly public company. The filing adds little beyond the numbers, but it sets a clean financial baseline for a company still proving itself to the market.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial